BioShield II May Revive Big Pharma’s Interest In Biodefense
Executive Summary
The proposed "BioShield II" legislation is reviving big pharma's interest in the biodefense industry, McKenna Long & Aldridge Partner Frank Rapoport maintained March 3 at Equity International's Homeland & Global Security Summit in Washington, D.C